New Predictive Model at 11+0to 13+6Gestational Weeks for Early-Onset Preeclampsia With Fetal Growth Restriction.
The aim of the present study was to determine a predictive model for early-onset preeclampsia with fetal growth restriction (FGR) to be used at 11+0to 13+6gestational weeks, by combining the maternal serum level of pregnancy-associated plasma protein-A (PAPP-A), placental growth factor (PLGF), placental protein 13 (PP13), soluble endoglin (sEng), mean arterial pressure (MAP), and uterine artery Doppler. This was a retrospective cohort study of 4453 pregnant women. Uterine artery Doppler examination was conducted in the first trimester. Maternal serum PAPP-A, PLGF, PP13, and sEng were measured. Mean arterial pressure was obtained. Women were classified as with/without early-onset preeclampsia, and women with preeclampsia were classified as with/without FGR. Receiver operating characteristic analysis was performed to determine the value of the model. There were 30 and 32 pregnant women with early-onset preeclampsia with and without FGR. The diagnosis rate of early-onset preeclampsia with FGR was 67.4% using the predictive model when the false positive rate was set at 5% and 73.2% when the false positive rate was 10%. The predictive model (MAP, uterine artery Doppler measurements, and serum biomarkers) had some predictive value for the early diagnosis (11+0to 13+6gestational weeks) of early-onset preeclampsia with FGR.
1 Obstetrics Department, Tianjin Center Hospital of Obstetrics and Gynecology, Tianjin, China.
Ying
Y
Chang
1 Obstetrics Department, Tianjin Center Hospital of Obstetrics and Gynecology, Tianjin, China.
Xu
X
Chen
1 Obstetrics Department, Tianjin Center Hospital of Obstetrics and Gynecology, Tianjin, China.
Hong-Yan
HY
Cui
1 Obstetrics Department, Tianjin Center Hospital of Obstetrics and Gynecology, Tianjin, China.
Xing
X
Li
1 Obstetrics Department, Tianjin Center Hospital of Obstetrics and Gynecology, Tianjin, China.
Ya-Ling
YL
Xu
D000328:Adult; D062186:Arterial Pressure; D015415:Biomarkers / Q000378:metabolism; D000071063:Endoglin / Q000097:blood; D005260:Female; D005317:Fetal Growth Retardation / Q000097:blood / Q000175:diagnosis* / Q000503:physiopathology; D037161:Galectins / Q000097:blood; D005865:Gestational Age; D006801:Humans; D011225:Pre-Eclampsia / Q000097:blood / Q000175:diagnosis* / Q000503:physiopathology; D011247:Pregnancy; D011257:Pregnancy Proteins / Q000097:blood; D011266:Pregnancy-Associated Plasma Protein-A / Q000378:metabolism; D012372:ROC Curve; D012189:Retrospective Studies; D018608:Ultrasonography, Doppler; D055988:Uterine Artery / Q000000981:diagnostic imaging
D015415:Biomarkers; C064206:ENG protein, human; D000071063:Endoglin; D037161:Galectins; C038195:LGALS13 protein, human; D011257:Pregnancy Proteins; D011266:Pregnancy-Associated Plasma Protein-A; C579283:PAPPA protein, human
early-onset preeclampsia; fetal growth restriction; first trimester; predictive model